Mass Customized Outlook for Regenerative Heart Failure Care

Heart failure pathobiology is permissive to reparative intent. Regenerative therapies exemplify an emerging disruptive innovation aimed at achieving structural and functional organ restitution. However, mixed outcomes, complexity in use, and unsustainable cost have curtailed broader adoption, mandat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Satsuki Yamada, Jozef Bartunek, Atta Behfar, Andre Terzic
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	acellular affordable cardiopoietic cardiopoiesis clinical trial cost Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/77a7cb6db3d240c2b82dd4dcbc7a2d8f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:77a7cb6db3d240c2b82dd4dcbc7a2d8f
record_format	dspace
spelling	oai:doaj.org-article:77a7cb6db3d240c2b82dd4dcbc7a2d8f2021-11-11T16:52:10ZMass Customized Outlook for Regenerative Heart Failure Care10.3390/ijms2221113941422-00671661-6596https://doaj.org/article/77a7cb6db3d240c2b82dd4dcbc7a2d8f2021-10-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/11394https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Heart failure pathobiology is permissive to reparative intent. Regenerative therapies exemplify an emerging disruptive innovation aimed at achieving structural and functional organ restitution. However, mixed outcomes, complexity in use, and unsustainable cost have curtailed broader adoption, mandating the development of novel cardio-regenerative approaches. Lineage guidance offers a standardized path to customize stem cell fitness for therapy. A case in point is the molecular induction of the cardiopoiesis program in adult stem cells to yield cardiopoietic cell derivatives designed for heart failure treatment. Tested in early and advanced clinical trials in patients with ischemic heart failure, clinical grade cardiopoietic cells were safe and revealed therapeutic improvement within a window of treatment intensity and pre-treatment disease severity. With the prospect of mass customization, cardiopoietic guidance has been streamlined from the demanding, recombinant protein cocktail-based to a protein-free, messenger RNA-based single gene protocol to engineer affordable cardiac repair competent cells. Clinical trial biobanked stem cells enabled a systems biology deconvolution of the cardiopoietic cell secretome linked to therapeutic benefit, exposing a paracrine mode of action. Collectively, this new knowledge informs next generation regenerative therapeutics manufactured as engineered cellular or secretome mimicking cell-free platforms. Launching biotherapeutics tailored for optimal outcome and offered at mass production cost would contribute to advancing equitable regenerative care that addresses population health needs.Satsuki YamadaJozef BartunekAtta BehfarAndre TerzicMDPI AGarticleacellularaffordablecardiopoieticcardiopoiesisclinical trialcostBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 11394, p 11394 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	acellular affordable cardiopoietic cardiopoiesis clinical trial cost Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	acellular affordable cardiopoietic cardiopoiesis clinical trial cost Biology (General) QH301-705.5 Chemistry QD1-999 Satsuki Yamada Jozef Bartunek Atta Behfar Andre Terzic Mass Customized Outlook for Regenerative Heart Failure Care
description	Heart failure pathobiology is permissive to reparative intent. Regenerative therapies exemplify an emerging disruptive innovation aimed at achieving structural and functional organ restitution. However, mixed outcomes, complexity in use, and unsustainable cost have curtailed broader adoption, mandating the development of novel cardio-regenerative approaches. Lineage guidance offers a standardized path to customize stem cell fitness for therapy. A case in point is the molecular induction of the cardiopoiesis program in adult stem cells to yield cardiopoietic cell derivatives designed for heart failure treatment. Tested in early and advanced clinical trials in patients with ischemic heart failure, clinical grade cardiopoietic cells were safe and revealed therapeutic improvement within a window of treatment intensity and pre-treatment disease severity. With the prospect of mass customization, cardiopoietic guidance has been streamlined from the demanding, recombinant protein cocktail-based to a protein-free, messenger RNA-based single gene protocol to engineer affordable cardiac repair competent cells. Clinical trial biobanked stem cells enabled a systems biology deconvolution of the cardiopoietic cell secretome linked to therapeutic benefit, exposing a paracrine mode of action. Collectively, this new knowledge informs next generation regenerative therapeutics manufactured as engineered cellular or secretome mimicking cell-free platforms. Launching biotherapeutics tailored for optimal outcome and offered at mass production cost would contribute to advancing equitable regenerative care that addresses population health needs.
format	article
author	Satsuki Yamada Jozef Bartunek Atta Behfar Andre Terzic
author_facet	Satsuki Yamada Jozef Bartunek Atta Behfar Andre Terzic
author_sort	Satsuki Yamada
title	Mass Customized Outlook for Regenerative Heart Failure Care
title_short	Mass Customized Outlook for Regenerative Heart Failure Care
title_full	Mass Customized Outlook for Regenerative Heart Failure Care
title_fullStr	Mass Customized Outlook for Regenerative Heart Failure Care
title_full_unstemmed	Mass Customized Outlook for Regenerative Heart Failure Care
title_sort	mass customized outlook for regenerative heart failure care
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/77a7cb6db3d240c2b82dd4dcbc7a2d8f
work_keys_str_mv	AT satsukiyamada masscustomizedoutlookforregenerativeheartfailurecare AT jozefbartunek masscustomizedoutlookforregenerativeheartfailurecare AT attabehfar masscustomizedoutlookforregenerativeheartfailurecare AT andreterzic masscustomizedoutlookforregenerativeheartfailurecare
_version_	1718432246304604160

Mass Customized Outlook for Regenerative Heart Failure Care

Ejemplares similares